Newsletter Tool

To view this email as a web page, click here

Today's Rundown

A COVID-19 vaccine in early November? 'Extremely unlikely, but not impossible': Warp Speed head Slaoui
Healthcare jobs grew by 75K in August as industry recovers from job losses due to COVID-19
Roche nets FDA authorization for combination COVID-19 and flu test
Pfizer, BioNTech 'quietly' usher a 5th COVID-19 jab into the clinic: analyst
Google, Oxford study projects benefits to coronavirus-tracing smartphone apps, even at low levels of adoption
3 questions every pediatrician needs to ask during the return to school
Biopharma roundup: AstraZeneca scores 5 Defense Department sites for U.S. phase 3; Johnson & Johnson's shot thwarts severe COVID-19 in hamster trial
Healthcare roundup: Allina Health, Aetna launch campaign urging patients to seek needed care
Independent, smaller hospitals will need to make tough choices to survive COVID-19 financial crisis: analysis

Featured Story

A COVID-19 vaccine in early November? 'Extremely unlikely, but not impossible': Warp Speed head Slaoui

By Eric Sagonowsky

With COVID-19 vaccine hype intensifying each day—including this week, with new comments from Pfizer’s CEO—the head of the U.S. government’s research program said it's "extremely unlikely" a vaccine will be available in early November.

Healthcare jobs grew by 75K in August as industry recovers from job losses due to COVID-19

By Robert King

The healthcare industry's job market continued to recover by adding 75,000 jobs in August, as hospitals continued to add more jobs after losses due to COVID-19.

Roche nets FDA authorization for combination COVID-19 and flu test

By Conor Hale

Roche announced the launch of its second COVID-19 diagnostic of the week after securing an FDA authorization for a test that detects the novel coronavirus as well as influenza A and B, as the pandemic is set to collide with the annual flu season.

Pfizer, BioNTech 'quietly' usher a 5th COVID-19 jab into the clinic: analyst

By Amirah Al Idrus

BioNTech and partner Pfizer have been working on four vaccine candidates against COVID-19, snagging FDA fast-track tags for two of them and pushing one into a 30,000-patient phase 3 study. Now, the duo is adding a fifth shot on goal, slated to enter a phase 1/2 study this month.

Google, Oxford study projects benefits to coronavirus-tracing smartphone apps, even at low levels of adoption

By Conor Hale

A study from Google and epidemiology researchers at Oxford University found that digital contract tracing using a network of smartphones could potentially help stem the spread of the novel coronavirus, even if a relatively small number of people download the app.

3 questions every pediatrician needs to ask during the return to school

By Jacqueline Renfrow

Although there is still so much that is unknown about COVID-19, physicians, especially pediatricians, have found themselves navigating an uncertain terrain of guiding parents through questions about going back to school safely.

Biopharma roundup: AstraZeneca scores 5 Defense Department sites for U.S. phase 3; Johnson & Johnson's shot thwarts severe COVID-19 in hamster trial

By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner

The U.S. Defense Department will provide five sites for AstraZeneca's U.S. vaccine trial. Merck may push two vaccine hopefuls into human testing this year. CureVac could make vaccines at scale by the year's end, an investor said. Animal data show J&J's shot curbed severe disease. Plus, Russia's shot yielded promising data, and the Philippines may want in.

Healthcare roundup: Allina Health, Aetna launch campaign urging patients to seek needed care

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Independent, smaller hospitals will need to make tough choices to survive COVID-19 financial crisis: analysis